Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PharmaMar, S.A.

Latest From PharmaMar, S.A.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Clinical Trials Companies

PharmaMar Victory Has EU Regulators Pondering Next Move

PharmaMar’s persistence has paid off in its fight to overturn the European Commission’s rejection of its marketing application for the multiple myeloma drug, Aplidin.

Legal Issues Approvals

Brexit: UK Joining US-Led Project Orbis To Speed Cancer Drug Approvals

Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.

United Kingdom International

EMA Wants Panexcell-Tested Generics Suspended; Spares Yondelis

The European Medicines Agency says that available evidence from a discontinued study does not call into question PharmaMar/Janssen’s Yondelis in its currently authorized uses. But in a separate recommendation it says that bioequivalence studies on generic drugs conducted by CRO Panexcell might be flawed.

Europe Drug Safety
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Grupo Zeltia
    • PharmaMar
    • Zeltia Group